tradingkey.logo

Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c

ReutersJun 23, 2025 8:58 PM

- Corcept Therapeutics Inc CORT.O:

  • CORCEPT PRESENTS DATA FROM TREATMENT PHASE OF CATALYST TRIAL AT AMERICAN DIABETES ASSOCIATION’S 85TH SCIENTIFIC SESSIONS WITH SIMULTANEOUS PUBLICATION IN DIABETES CARE

  • CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN HBA1C

  • CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS SECONDARY ENDPOINTS WITH REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI